Alizapride-13C,d3 (hydrochloride)

Alizapride-13C,d3 (hydrochloride)

• UNSPSC Description: Alizapride-13C,d3 (hydrochloride) is deuterium labeled Alizapride (hydrochloride). Alizapride hydrochloride is a dopamine receptor antagonist with prokinetic and antiemetic effects which can also be used in the treatment of nausea and vomiting, including postoperative nausea and vomiting.
• Target Antigen: Dopamine Receptor; Isotope-Labeled Compounds
• Type: Isotope-Labeled Compounds
• Related Pathways: GPCR/G Protein;Neuronal Signaling;Others
• Applications: Cancer-programmed cell death
• Field of Research: Cancer; Neurological Disease
• Solubility: 10 mM in DMSO
• Smiles: O=C(C1=CC2=C(C=C1O[13C]([2H])([2H])[2H])NN=N2)NCC3N(CCC3)CC=C.Cl
• Molecular Weight: 355.84
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Bleiberg H, et al. Activity of a new antiemetic agent: alizapride. A randomized double-blind crossover controlled trial. Cancer Chemother Pharmacol. 1988;22(4):316-20.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported